Your browser doesn't support javascript.
loading
Qili Qiangxin (QLQX) capsule as a multi-functional traditional Chinese medicine in treating chronic heart failure (CHF): A review of ingredients, molecular, cellular, and pharmacological mechanisms.
Wang, Tongxing; Hou, Bin; Qin, Haoran; Liang, Junqing; Shi, Min; Song, Yanfei; Ma, Kun; Chen, Meng; Li, Huixin; Ding, Guoyuan; Yao, Bing; Wang, Zhixin; Wei, Cong; Jia, Zhenhua.
Afiliação
  • Wang T; National Key Laboratory of Luobing Research and Innovative Chinese Medicine, Shijiazhuang 050035, China.
  • Hou B; Key Laboratory of State Administration of TCM (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang 050035, China.
  • Qin H; National Key Laboratory of Luobing Research and Innovative Chinese Medicine, Shijiazhuang 050035, China.
  • Liang J; Key Laboratory of State Administration of TCM (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang 050035, China.
  • Shi M; Department of Integrative Oncology, Changhai Hospital, Naval Military Medical University, Shanghai 200438, China.
  • Song Y; National Key Laboratory of Luobing Research and Innovative Chinese Medicine, Shijiazhuang 050035, China.
  • Ma K; Key Laboratory of State Administration of TCM (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang 050035, China.
  • Chen M; National Key Laboratory of Luobing Research and Innovative Chinese Medicine, Shijiazhuang 050035, China.
  • Li H; Key Laboratory of State Administration of TCM (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang 050035, China.
  • Ding G; Key Disciplines of State Administration of TCM for Luobing, Hebei Academy of Interactive Medicine, Shijiazhuang 050035, China.
  • Yao B; Shijiazhuang Compound Traditional Chinese Medicine Technology Innovation Center, Shijiazhuang 050035, China.
  • Wang Z; Hebei Provincial Key Laboratory of Luobing, Shijiazhuang 050035, China.
  • Wei C; Hebei Provincial Key Laboratory of Luobing, Shijiazhuang 050035, China.
  • Jia Z; Key Disciplines of State Administration of TCM for Luobing, Hebei Academy of Interactive Medicine, Shijiazhuang 050035, China.
Heliyon ; 9(11): e21950, 2023 Nov.
Article em En | MEDLINE | ID: mdl-38034785
ABSTRACT
Chronic heart failure (CHF) is a key part of cardiovascular continuum. Under the guidance of the theory of vessel-collateral doctrine, the present study proposes therapeutic benefits of Qili Qiangxin (QLQX) capsules, an innovative Chinese medicine, on chronic heart failure. The studies show that multiple targets of the drug on CHF, including enhancing myocardial systole, promoting urine excretion, inhibiting excessive activation of the neuroendocrine system, preventing ventricular remodeling by inhibiting inflammatory response, myocardial fibrosis, apoptosis and autophagy, enhancing myocardial energy metabolism, promoting angiogenesis, and improving endothelial function. Investigation on the effects and mechanism of the drug is beneficial to the treatment of chronic heart failure (CHF) through multiple targets and/or signaling pathways. Meanwhile, it provides new insights to further understand other refractory diseases in the cardiovascular continuum, and it also has an important theoretical and practical significance in enhancing prevention and therapeutic effect of traditional Chinese medicine for these diseases.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article